Argitalpenak (314) Domingo Andres Pascual Figal argitalpenak

2024

  1. Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutations

    European Heart Journal

  2. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials

    eClinicalMedicine, Vol. 76

  3. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

  4. Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study

    Journal of Cardiac Failure, Vol. 30, Núm. 3, pp. 425-435

  5. Effectiveness and safety of non-invasive ventilation in the management of cardiogenic shock

    Revista Portuguesa de Cardiologia, Vol. 43, Núm. 5, pp. 259-273

  6. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review

    Frontiers in Cardiovascular Medicine, Vol. 11

  7. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease

    Archivos de Bronconeumologia, Vol. 60, Núm. 4, pp. 226-237

  8. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 776-784

  9. Semi-quantitative pulmonary congestion score: prevalence and diuretic management implications after heart failure discharge

    Revista Clinica Espanola, Vol. 224, Núm. 3, pp. 157-161

  10. The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study

    Nutrients, Vol. 16, Núm. 8

  11. Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 851-858

2023

  1. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome

    GeroScience, Vol. 45, Núm. 2, pp. 1231-1236

  2. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  3. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  4. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  5. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  6. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 389-398

  7. Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients

    IJC Heart and Vasculature, Vol. 46

  8. Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 80-89

  9. Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

    European heart journal